Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its
manufacturing partner, Aldevron, has successfully completed the manufacturing
of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing
agreement between the companies that was disclosed in September 2018. According
to the update, Genprex’s Oncoprex(TM), the company’s initial product candidate,
consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a
nanovesicle made from lipid molecules with a positive electrical charge.
Historically, manufacturing steps have been done for Genprex at MD Anderson
Cancer Center, but, since Genprex’s IPO, the company has been working to
transfer and scale up these processes through other contract manufacturers.
“Each successful release of plasmid DNA batches is an important milestone for
Genprex as it allows us to not only demonstrate continued progress in
coordinating scale-up manufacturing of Oncoprex, but it takes us one step
closer to re-entering the clinic with both our EGFR program and our
immunotherapy combination programs,” Genprex President and Chief Operating
Officer Julien Pham, MD, said in the news release. “Biologics manufacturing,
especially for lipid nanoparticle (or ‘LNP’) delivered gene therapy, is a
complex process, but one we tackle with pride alongside dedicated partners such
as Aldevron, through a similar vision to deliver innovative therapies to
patients with significant unmet medical needs.”
To view the full press release, visit http://ibn.fm/V3rjj
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s initial
product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer
(NSCLC). Genprex’s platform technologies are designed to administer cancer
fighting genes by encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken up by tumor
cells where they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts cell
signaling pathways that cause replication and proliferation of cancer cells,
re-establishes pathways for apoptosis, or programmed cell death, in cancer
cells, and modulates the immune response against cancer cells. Oncoprex has
also been shown to block mechanisms that create drug resistance. For more
information, visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
